MiMedx Group Inc. (MDXG)
NASDAQ:MDXG
Earnings Data
Report Date
May 05, 2026Before Open (Not Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.02Last Year’s EPS
0.05Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlights a strong 2025 with record revenue, margin expansion and a fortified balance sheet, plus clear growth momentum and product/clinical progress in the Surgical segment. However, substantial near-term headwinds in the Wound Care market — driven by Medicare reimbursement changes, pricing disruption, prior-authorization delays and uncertainty around market sizing — lead management to guide to a lower revenue and margin profile for 2026. The company emphasizes confidence in its long-term positioning and expects recovery and above-market growth by 2027, but acknowledges a noisy transition year ahead.Company Guidance
Record Full-Year Financial Performance
Net sales of $419 million in 2025, representing 20% year-over-year growth; full-year adjusted EBITDA of nearly $106 million (approximately 25% adjusted EBITDA margin); GAAP net income of $49 million.
Strong Fourth Quarter Results
Q4 2025 net sales of $118 million, up 27% year-over-year; Wound sales $79 million (+28% YoY) and Surgical sales $39 million (+25% YoY); Q4 adjusted gross profit margin 86%; Q4 adjusted EBITDA $29 million (25% of net sales); Q4 GAAP net income $15 million ($0.10/share) and adjusted net income $20 million ($0.14/share).
Robust Balance Sheet and Cash Generation
Net cash balance of $148 million at year-end (up $24 million sequentially and ~$63 million year-over-year); Q4 free cash flow of $25 million; Board authorized share repurchase program up to $100 million over two years, providing capital flexibility.
Surgical Business Momentum and Growth
Surgical segment grew ~20% for full year 2025 and 25% in Q4; management expects continued momentum and a Surgical run-rate approaching ~$200 million by year-end as commercial investments and new product introductions scale.
Pipeline and Clinical Progress
EPIEFFECT randomized controlled trial nearly fully enrolled with a readout expected in a few months; committed to an RCT for CHORIOFIX; recent peer-reviewed publication (Journal of Inflammation) supporting immunomodulatory properties of DHACM/LHACM allografts.
Product Expansion and Strategic Partnerships
Launched AMNIOFIX Thyroid Shield; licensed three 510(k)-cleared complementary surgical products (NovaForm Wound Matrix, G4Derm Plus, Hydrelix Collagen Matrix); entered a distribution agreement for RegenKit Wound Gel (PRP) to broaden wound modality offerings.
Improved Gross Margin Driven by Product Mix
GAAP gross margin improved to ~84% in Q4 (from 82% prior year); non-GAAP adjusted gross margin was 86% in Q4, up ~200 basis points YoY, driven primarily by favorable product mix.
MDXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $5.28 | $4.94 | -6.44% |
Oct 29, 2025 | $7.19 | $7.40 | +2.92% |
Jul 30, 2025 | $6.52 | $7.19 | +10.28% |
Apr 30, 2025 | $6.88 | $6.32 | -8.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MiMedx Group Inc. (MDXG) report earnings?
MiMedx Group Inc. (MDXG) is schdueled to report earning on May 05, 2026, Before Open (Not Confirmed).
What is MiMedx Group Inc. (MDXG) earnings time?
MiMedx Group Inc. (MDXG) earnings time is at May 05, 2026, Before Open (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXG EPS forecast?
MDXG EPS forecast for the fiscal quarter 2026 (Q1) is -0.02.